A rapidly emerging category in our healthcare industry is Remote Patient Monitoring (RPM).
18% of the U.S. GDP is consumed by healthcare costs. 80% of that 18% is spent on managing chronic illnesses.
Dr. Waqaas Al-Siddiq, DBA, the Founder and CEO of Biotricity Inc. (NASDAQ:BTCY) joined me with Dragonfly Stories – A Mullings Group Company in One60Studios to discuss his unique remote patient monitoring platform.
If appropriately deployed, managed, and acted upon, the RPM space has the potential to react to those consumers/patients diagnosed with a chronic disease.
Perhaps even as powerful, the platform potentially allows for those identified as being predisposed for a disease as determined by genetic testing, providing an opportunity to react to sub-clinical signals with an early and less acute and costly intervention.
That intervention may be diet, prescription drugs, exercise, and/or lifestyle adjustments.
Afterall, genetics loads the gun, lifestyle and environment fires it.
Why are we not mining that evidence?